What is the definitive diagnostic test to confirm leukemia?

Main Diagnostic Test for Leukemia

Bone marrow (BM) aspirate with morphologic evaluation, combined with flow cytometry immunophenotyping and conventional cytogenetic analysis (karyotype), is the definitive diagnostic test to confirm leukemia. 1

Core Diagnostic Approach

The diagnostic workup requires a systematic, multi-step process:

Initial Screening

• Review peripheral blood (PB) smear with complete blood count (CBC) and leukocyte differential as the first step 1
• If sufficient blasts are present in peripheral blood, diagnosis can be established from PB alone when bone marrow examination is contraindicated or unobtainable 1

Definitive Tissue Diagnosis

Bone marrow examination is the gold standard and includes: 1

• Fresh BM aspirate for morphologic evaluation on aspirate smears (strong recommendation)
• BM trephine core biopsy evaluated in conjunction with aspirates
• Touch preparations and/or marrow clots if available
• If BM aspirate yields a "dry tap," touch imprint preparations of the core biopsy should be prepared 1

Essential Ancillary Testing

The following must be performed on adequate samples to establish a complete diagnosis: 1

• Flow cytometry immunophenotyping (FCI) - comprehensive panel sufficient to distinguish AML (including APL), early T-ALL, B-ALL, and acute leukemia of ambiguous lineage 1
• Conventional cytogenetic analysis (karyotype) - this is mandatory and cannot be replaced by molecular testing 1
• Molecular genetic and/or FISH testing - appropriate for the suspected leukemia subtype 1

Alternative Specimen Sources

When bone marrow cannot be obtained: 1

• Peripheral blood may be used if sufficient blast numbers are present (typically ≥5 × 10⁹/L for diagnosis)
• An additional core biopsy can be submitted unfixed in tissue culture medium for disaggregation for flow cytometry and genetic studies 1
• For extramedullary disease without BM/blood involvement, tissue biopsy must be processed for morphologic, immunophenotypic, cytogenetic, and molecular genetic studies 1

Critical Pitfalls to Avoid

Do not rely on peripheral blood alone when bone marrow is accessible - even if PB shows blasts, BM examination provides superior information for classification, prognostication, and treatment planning 1

Do not substitute FISH or molecular testing for conventional karyotyping - karyotype analysis detects unexpected chromosomal abnormalities that targeted testing would miss 1

Ensure adequate sample collection - obtain sufficient material at initial diagnostic procedure for all required testing (morphology, flow cytometry, cytogenetics, molecular studies) to avoid repeat procedures 1

Supporting Laboratory Studies

Additional baseline testing recommended: 1

• Comprehensive metabolic panel, lactate dehydrogenase, phosphate, and uric acid (to assess tumor lysis syndrome risk)
• Coagulation panel including PT, PTT, and fibrinogen (especially if acute promyelocytic leukemia is suspected to detect disseminated intravascular coagulation)
• CSF examination for ALL patients or when CNS involvement is suspected 1

Specimen Processing Requirements

Optimal handling ensures diagnostic accuracy: 1

• The same physician should interpret BM aspirate smears and core biopsy, or interpretations should be correlated if performed by different physicians 1
• Specimens for molecular/genetic studies must be properly identified and stored under appropriate conditions in accredited laboratories 1
• Cryopreserved cells or nucleic acid should be obtained for future molecular studies where validated 1